Genome plasmid for Edinburgh's trial comes from Indiana University
- University of Edinburgh
- Open, 1 bid
The University of Edinburgh bought a custom plasmid from Indiana University for a planned clinical trial. The therapy under trial is for children with a rare genetic condition that brings on progressive dementia.
The plasmid is used to make a lentiviral vector, which modifies patients' own stem cells to deliver an enzyme to the central nervous system. Indiana University had to make it to an FDA IND-ready standard and ship it straight to the University of Edinburgh's partner, the University of California Los Angeles. Tests for endotoxin, identity and purity were part of the order, and delivery was due within two months of the contract being signed.
Bidders had to have supplied a plasmid to this specification for a similar trial before. Indiana University's was the only bid, and the award was £75,135.
- What
- Aseptic compounding, specials and contract pharmaceutical manufacturing
- Supplier
- Indiana University
- Value
- £75,135
- How it was bought
- Open
- 1 bid
- Dates and next
- 14 Aug 2025